Vilaprisan (BAY1002670)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical Trial, Phase I
Conditions
Clinical Trial, Phase I
Trial Timeline
Oct 1, 2014 → Dec 1, 2015
NCT ID
NCT02262663About Vilaprisan (BAY1002670)
Vilaprisan (BAY1002670) is a phase 1 stage product being developed by Bayer for Clinical Trial, Phase I. The current trial status is completed. This product is registered under clinical trial identifier NCT02262663. Target conditions include Clinical Trial, Phase I.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03476928 | Phase 3 | Terminated |
| NCT03411980 | Phase 1 | Completed |
| NCT03240523 | Phase 3 | Terminated |
| NCT03092999 | Phase 1 | Completed |
| NCT02262663 | Phase 1 | Completed |
Competing Products
20 competing products in Clinical Trial, Phase I